Compare Becton Dickinson and Co (BDX) vs Chart Industries Inc (GTLS) Price & Performance

BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.

The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.

GTLS trades at $209.79, showing minimal daily movement with a -0.04% decline. The stock maintains a bullish technical signal despite recent earnings misses, with Q2 2026 results pending. Valuation metrics show elevated P/E at 629.67 but reasonable P/S at 2.33. The company faces profitability challenges with negative net income margin and ROE, though operating cash flow remains positive at $293M. Recent news highlights Baker Hughes' $13.6 billion acquisition progressing through regulatory approval.

The outlook remains cautiously optimistic given strong analyst support (54% buy rating) and the pending acquisition catalyst. However, consecutive earnings misses and negative profitability metrics present near-term risks. The technical setup suggests potential support at current levels, but fundamental improvement is needed to justify the premium valuation multiple.